InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,633.91
(
1.02%
)
US TECH 100
20,118.40
(
0.00%
)
Dow Jones
39,721.36
(
1.09%
)
Brent Oil
85.19
(
0.16%
)
Bitcoin
57,982.35
(
0.39%
)
Post# of 252557
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Double_Bagel

Send PM Follow Ignore
Followers 14
Posts 898
Boards Moderated 0
Alias Born 03/07/2011

Double_Bagel

Re: None

Thursday, 08/04/2016 7:31:58 AM

Thursday, August 04, 2016 7:31:58 AM

Post# of 252557
Teva reports Q2 EPS $1.25, consensus $1.20

Reports Q2 revenue $5.0B, consensus $4.87B.

Reports:
-- Copaxone revenue up 8% to $1.14B
-- Treanda and Bendeka revenue up 16% to $207M (from 179 million)

Teva's Investor Relations

Note: That is a huge jump from the previous quarter which was 155 million. So, Qtr-by-qtr increase from 155 million to 207 million. (33%). The first qtr of 2015 had sales of 157 million.

Can anybody figure out what is the royalty owed to EGRX for the quarter?
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up